A Phase 2 interventional study of PTG-300 in β-thalassemia and Ineffective Erythropoiesis, sponsored by Protagonist Therapeutics, Inc.. Completed at 16 sites in 8 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-16.
Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Thalassemia with a site in Thailand — none open to participants now, 3 under way, 2 of them phase 3. Thalassemia · Thailand.
Among the 24 studies in Thalassemia with a site in Thailand, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2019, is one of 11 in phase 2, and was the 18th registered.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
Browse Thalassemia studies →None of the 24 studies in Thalassemia with a site in Thailand is open now. The open studies under Thalassemia, anywhere →
Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is close to the median of 33 across 170 interventional studies indexed under Thalassemia.
Median enrollment 99 across the 22 interventional studies, 109 across the 2 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 24 have an industry lead sponsor. The 10 most frequent:
Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Protagonist Therapeutics, Inc. has 2 studies filed under Thalassemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Thalassemia with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
The PTG-300-03 study will study beta thalassemia patients on PTG-300 for two years. The dose and dose frequency for each subject enrolling in the PTG-300-03 study will be based on the last dose and frequency received by the subject in the previous study PTG-300-02 and the subject's response at that dose. Patients dose will be increased in a manner similar to that used on PTG-300-02 study. The maximum PTG-300 dose allowed is 80 mg/week.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PTG-300
Drug: PTG-300
PTG-300 is a hepcidin Mimetic
Proportion of subjects with side effects and severity of side effects will be tabulated
the long-term safety and tolerability of PTG-300 in Beta Thalassemia.
Time frame: Over two year Period after receiving PTG-300
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2019 to primary completion in Jul 2020, 14 months.
Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rusfertide
Protagonist Therapeutics, Inc.